GlassScriptPhysician profile
Erica Sperduto
NPI 1508312539
$1,806.74
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $489 · 2022: $824 · 2023: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $255.25 | 2021-2023 | Repatha, Otezla |
| Abbvie INC. | $217.42 | 2022-2023 | |
| Abbott Laboratories | $158.58 | 2022-2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $141.31 | 2021-2023 | |
| Novo Nordisk INC | $138.59 | 2021-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $131.54 | 2021-2023 | Mounjaro |
| Esperion Therapeutics, INC. | $119.13 | 2021-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $117.79 | 2021-2023 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.66 | 2021-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $88.25 | 2022 | |
| Xeris Pharmaceuticals, INC. | $77.42 | 2022-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $72.94 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $55.33 | 2021 | |
| Glaxosmithkline, LLC. | $54.38 | 2022-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.23 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.90 | 2022 | |
| Dexcom, INC. | $14.09 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $13.84 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Sperduto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.